Top alopecia, hair loss research of 2016

Research finding that Xeljanz for adolescents with alopecia areata resulted in significant hair regrowth for the majority of the patients was among the most-read articles in 2016 regarding hair loss treatments on Healio.com/Dermatology.

Other widely read articles included research on topical Jakafi to treat alopecia universalis and platelet-rich plasma to treat androgenetic alopecia:

Topical Jakafi successfully treats alopecia universalis

A patient in her late teens with alopecia universalis was successfully treated with topical Jakafi, with minimal adverse effects, according to study results published in JAMA Dermatology.

Brett A. King, MD, PhD, and colleagues studied the patient who presented with alopecia universalis. Read more

VIDEO: Amy J. McMichael, MD, reviews new topical treatment for hair loss

WASHINGTON – In a video perspective, Amy J. McMichael, MD, discusses research she reviewed on qilib, a new over-the-counter topical treatment for hair loss.

Amy McMichael, MD
Amy J. McMichael

The qilib hair care line (Galderma Laboratories) uses a solution formulated with botanicals, including an onion extract as its active ingredient, in conjunction with 2% minoxidil for women and 5% minoxidil for men. It was introduced at the American Academy of Dermatology Annual Meeting. Watch video

Early androgenetic alopecia in men considered phenotypic equivalent of PCOS in women

Men with early androgenic alopecia, or patterned hair loss before age 30, could be considered phenotypic equivalents to women with polycystic ovarian syndrome and may have the same health risks, according to study results published in JAMA Dermatology.

he researchers conducted a case-control study of 57 men aged 19 to 30 years (mean age, 24.7 years) with androgenic alopecia who presented between Jan. 1, 2014, and March 31, 2015 to a tertiary care government hospital in New Delhi, India. Read more

Xeljanz shows promise as treatment for alopecia areata in adolescents

Treatment with Xeljanz in adolescents with alopecia areata resulted in significant hair regrowth for the majority of the patients, with mild adverse events, according to recently published study results.

Brent A. King, MD, PhD, assistant professor of dermatology, Yale School of Medicine, and colleagues studied 13 adolescent patients (median age 15 years; 77% male) with alopecia areata treated with Xeljanz (tofacitinib, Pfizer) between July 2014 and May 2016 at a tertiary care center clinic. Read more

Platelet-rich plasma shows positive effect on androgenetic alopecia

Patients who received a half-head treatment of platelet-rich plasma to treat androgenetic alopecia showed a clinical benefit at 6-month follow-up, according to research.

“This clinical research provides support that the application of [platelet-rich plasma] may have a therapeutic effect on [androgenetic alopecia] and can be used as a safe complementary treatment option,” Rubina Alves, MD, from the department of dermatology at the Universitat Internacional de Catalunya in Barcelona, Spain and colleagues wrote in their study. Read more

Research finding that Xeljanz for adolescents with alopecia areata resulted in significant hair regrowth for the majority of the patients was among the most-read articles in 2016 regarding hair loss treatments on Healio.com/Dermatology.

Other widely read articles included research on topical Jakafi to treat alopecia universalis and platelet-rich plasma to treat androgenetic alopecia:

Topical Jakafi successfully treats alopecia universalis

A patient in her late teens with alopecia universalis was successfully treated with topical Jakafi, with minimal adverse effects, according to study results published in JAMA Dermatology.

Brett A. King, MD, PhD, and colleagues studied the patient who presented with alopecia universalis. Read more

VIDEO: Amy J. McMichael, MD, reviews new topical treatment for hair loss

WASHINGTON – In a video perspective, Amy J. McMichael, MD, discusses research she reviewed on qilib, a new over-the-counter topical treatment for hair loss.

Amy McMichael, MD
Amy J. McMichael

The qilib hair care line (Galderma Laboratories) uses a solution formulated with botanicals, including an onion extract as its active ingredient, in conjunction with 2% minoxidil for women and 5% minoxidil for men. It was introduced at the American Academy of Dermatology Annual Meeting. Watch video

Early androgenetic alopecia in men considered phenotypic equivalent of PCOS in women

Men with early androgenic alopecia, or patterned hair loss before age 30, could be considered phenotypic equivalents to women with polycystic ovarian syndrome and may have the same health risks, according to study results published in JAMA Dermatology.

he researchers conducted a case-control study of 57 men aged 19 to 30 years (mean age, 24.7 years) with androgenic alopecia who presented between Jan. 1, 2014, and March 31, 2015 to a tertiary care government hospital in New Delhi, India. Read more

Xeljanz shows promise as treatment for alopecia areata in adolescents

Treatment with Xeljanz in adolescents with alopecia areata resulted in significant hair regrowth for the majority of the patients, with mild adverse events, according to recently published study results.

Brent A. King, MD, PhD, assistant professor of dermatology, Yale School of Medicine, and colleagues studied 13 adolescent patients (median age 15 years; 77% male) with alopecia areata treated with Xeljanz (tofacitinib, Pfizer) between July 2014 and May 2016 at a tertiary care center clinic. Read more

Platelet-rich plasma shows positive effect on androgenetic alopecia

Patients who received a half-head treatment of platelet-rich plasma to treat androgenetic alopecia showed a clinical benefit at 6-month follow-up, according to research.

“This clinical research provides support that the application of [platelet-rich plasma] may have a therapeutic effect on [androgenetic alopecia] and can be used as a safe complementary treatment option,” Rubina Alves, MD, from the department of dermatology at the Universitat Internacional de Catalunya in Barcelona, Spain and colleagues wrote in their study. Read more